Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction
about
Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's diseaseImpacts of cigarette smoking on immune responsiveness: Up and down or upside down?Milk casein-based diet containing TGF-beta controls the inflammatory reaction in the HLA-B27 transgenic rat modelImmune therapy in inflammatory bowel disease and models of colitis.Medical applications of transforming growth factor-betaImmunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection.Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides.Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease.Antisense approach to inflammatory bowel disease: prospects and challenges.Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor betaImmunoregulation in the gut: success and failures in human disease.Cytokine-induced alterations of α7 nicotinic receptor in colonic CD4 T cells mediate dichotomous response to nicotine in murine models of Th1/Th17- versus Th2-mediated colitis.Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis.The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodelingProtective Effect of Anthocyanins Extract from Blueberry on TNBS-Induced IBD Model of MiceGene transfer approaches for the treatment of inflammatory bowel disease.Immune networks in animal models of inflammatory bowel disease.Mechanisms of Intestinal Serotonin Transporter (SERT) Upregulation by TGF-β1 Induced Non-Smad PathwaysProtective effect of angelica sinensis polysaccharide on experimental immunological colon injury in rats.Novel drug delivery strategies for the treatment of inflammatory bowel disease.The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease.Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis.Intestinal epithelial cell signalling and host-derived negative regulators under chronic inflammation: to be or not to be activated determines the balance towards commensal bacteria.T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells.Immunopathogenesis of IBD: insufficient suppressor function in the gut?Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation.Lactococcus lactis carrying the pValac eukaryotic expression vector coding for IL-4 reduces chemically-induced intestinal inflammation by increasing the levels of IL-10-producing regulatory cellsRegulation of the mucosal phenotype in dendritic cells by PPARγ: role of tissue microenvironment.Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccinesProteomics at the interface of psychology, gut physiology and dysfunction: an underexploited approach that deserves expansion.Intestinal intraepithelial lymphocytes sustain the epithelial barrier function against Eimeria vermiformis infection.Transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation.Engineered E. coli delivers therapeutic genes to the colonic mucosa.Suppressor of cytokine signalling 1 in lymphocytes regulates the development of intestinal inflammation in miceT-cell regulation of neutrophil infiltrate at the early stages of a murine colitis model.Prevention of fibrosis in experimental colitis by captopril: the role of tgf-beta1.Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis.Effects of spinal non-viral interleukin-10 gene therapy formulated with d-mannose in neuropathic interleukin-10 deficient mice: Behavioral characterization, mRNA and protein analysis in pain relevant tissues.Anti-inflammatory actions of phosphatidylinositol.
P2860
Q24610206-614A4D30-6F33-4A9A-BE0D-1A3D33064275Q26745717-6BC1F8D6-1D23-4045-8D52-072D4CF69D36Q28072341-0B12A389-1C9E-4FF5-8F11-2DA429EF3EB6Q28573216-FDB25346-6D34-42E6-8CDA-D77E3F2A2A29Q30774968-66E2F91C-4EEF-4EDF-BB23-3EAD99452EACQ33723271-BB7CF31A-5167-4B0C-90CA-8E0A4AEEB1A1Q33930475-4BC96643-5D20-4CFE-B9AA-BF6B5C827826Q34084499-0A0DC4D0-F156-4B35-A39B-7EF038F867D8Q34233126-6D80FC99-3AE4-464E-9B23-761696799362Q34473572-BBE8AB76-0160-4519-82E3-E3AF469E10E5Q34517421-C6D1FB7A-82F5-426D-B4B7-0C88E3444DBCQ34601009-7842FA32-7262-46F6-9C54-AB9BBA918D79Q34662156-33600BD9-C3F9-47B8-A3B4-052E29C3E288Q34669243-C22FA8F1-200F-44CA-972B-5C8669D2A520Q34989767-19740B8F-187D-4E01-882D-5A6253789380Q35103711-8E2BDCA5-5B9C-4BF3-99B8-177333ABE650Q35122162-8041ECBE-37EA-451C-8D75-B840F4897A34Q35193871-EC4436EA-B65A-4AAE-9533-538D270BB48FQ35625107-EA22344D-BB92-4732-BF01-F9C55EC6AD3BQ36180541-61DE4097-C46D-4039-9CA9-0D6B61044B73Q36316765-CEE3562F-130C-4116-9FA5-7489AD0F98D8Q36370178-F34A1AD8-560E-4E9F-8232-6A1A482741A1Q36371784-676D16BF-76D7-4771-9268-851982CCDDD0Q36399968-5AED5567-563B-49FA-B143-2841F3900207Q36402737-90CC8E03-A835-4A60-8B7A-72D5FB36074CQ36626285-219A0B7E-628F-40AB-A71B-3BE8D44052B8Q36809889-5791D3A7-253D-4779-89E4-7F4526960058Q37220886-1CE96A78-F1A3-4B8F-8590-FF9BDD588B37Q37581433-68D9755C-2DC7-496F-8E36-460885F27570Q37590337-2BFDE194-1CAB-4B20-A8C2-943063F4BE95Q37945789-DBF4977D-3DE3-4942-B99C-19413CBB3A0EQ38481730-8F15D596-AEF3-4DA9-916B-474AC55A4B81Q40658888-74BF901A-0C83-466C-8BD6-9C9DB551E161Q41458834-C9FCA9C4-77FF-4E45-9A78-17311327B928Q42243167-D85D986F-A716-48A4-838F-A592BF9B1B04Q43284324-4B5BF81B-75C5-4DFE-B7A4-0832DC82626DQ45096816-667FBF5A-7690-4EE4-A365-547409EB8A5CQ45282194-C437DB74-22CA-4D2A-A565-83E3AC80C98EQ45874115-BAE6D5D0-7134-43D0-9DFD-051B3343F292Q45919766-6DD8EE6A-7206-4AB9-91DC-0C34B9B2A237
P2860
Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Treatment of experimental (Tri ...... interleukin (IL)-10 induction
@nl
type
label
Treatment of experimental (Tri ...... interleukin (IL)-10 induction
@nl
prefLabel
Treatment of experimental (Tri ...... interleukin (IL)-10 induction
@nl
P2093
P2860
P3181
P356
P1476
Treatment of experimental (Tri ...... tor beta2 chain downregulation
@en
P2093
P2860
P3181
P356
10.1084/JEM.192.1.41
P407
P577
2000-07-03T00:00:00Z